rsrc2 Antibody

What is RSRC2 and why is it significant in cellular biology?

RSRC2 (arginine/serine-rich coiled coil 2) is an RNA-binding protein containing an arginine- and serine-rich region, a coiled-coil domain, and a small acidic protein-like (SMAP) domain at its C-terminus. Research has revealed that RSRC2 plays essential roles in:

• Cell division through its interaction with the long non-coding RNA C1QTNF1-AS1

• Splicing regulation for specific mitotic genes

• Recruitment to mitotic centrosomes

• Tumor suppression in multiple cancer types

Notably, RSRC2 contains long N-terminal stretches of amino acids forming intrinsically disordered regions (IDRs), which can mediate RNA binding in non-canonical RNA-binding proteins .

How can I verify the specificity of an RSRC2 antibody?

Verification of RSRC2 antibody specificity is a crucial preliminary step. Recommended methodological approaches include:

• siRNA knockdown validation: Deplete RSRC2 using a pool of four siRNAs and confirm knockdown efficiency by qPCR and Western blot

• Immunofluorescence analysis: Compare staining patterns between control and RSRC2-depleted cells

• Subcellular localization confirmation: Verify nuclear localization and formation of distinct patches resembling nuclear speckles, with approximately 50% colocalization with SC35 (a nuclear speckle marker)

• Centrosomal localization: Confirm presence on mitotic centrosomes through co-staining with centrin (Cen 2/3) in control versus RSRC2-depleted cells

Research has demonstrated that high-quality RSRC2 antibodies show significant reduction in fluorescence intensity after siRNA-mediated depletion of RSRC2 .

What are the optimal conditions for immunoprecipitation using RSRC2 antibodies?

For successful immunoprecipitation of RSRC2 and its interacting partners:

• Use whole-cell extracts from your cell line of interest (HCT116 cells have been validated)

• Include appropriate controls (matched IgG control antibody)

• Consider parallel experiments with and without RNase A/T1 treatment to distinguish RNA-dependent versus RNA-independent interactions

• Verify immunoprecipitation efficiency through Western blot before proceeding to downstream applications such as mass spectrometry

• For RNA-protein interaction studies, consider techniques such as the incPRINT assay, which has been validated for detecting RSRC2-RNA interactions

Using these conditions, researchers have successfully identified 123 proteins that significantly interact with RSRC2, including splicing factors and centrosome proteins .

How should I optimize immunofluorescence protocols for RSRC2 antibody staining?

For optimal immunofluorescence results with RSRC2 antibodies:

• Fixation method: 4% paraformaldehyde provides good preservation of nuclear structures

• Permeabilization: Use 0.1% Triton X-100 to allow antibody access while preserving nuclear architecture

• Blocking: 5% BSA in PBS for 1 hour at room temperature helps reduce background

• Primary antibody dilution: Test a range from 1:100 to 1:500 to optimize signal-to-noise ratio

• Co-staining recommendations:

  • For nuclear speckle localization: Co-stain with SC35 antibody

  • For centrosomal localization: Co-stain with centrin (Cen 2/3) antibody

• Image analysis: Use Manders colocalization coefficient to quantify the degree of colocalization between RSRC2 and other markers

These optimizations have allowed researchers to verify that RSRC2 forms distinct patches in nuclei resembling nuclear speckles and localizes to mitotic centrosomes .

How can RSRC2 antibodies be utilized to investigate mitotic defects in cancer cell lines?

RSRC2 antibodies can be instrumental in investigating the role of RSRC2 in mitotic fidelity:

• Chromosome congression analysis:

  • Co-stain with CREST (centromere marker) and α-tubulin antibodies

  • Quantify chromosome congression defects in control versus RSRC2-depleted cells

  • Compare with cells depleted of known RSRC2 splicing targets such as PCNT

• Centrosome integrity assessment:

  • Analyze centrin levels in control versus RSRC2-depleted cells

  • Quantify centriole assembly defects during mitosis

  • Investigate the impact on spindle formation and chromosome alignment

• Rescue experiments:

  • Re-express RSRC2 in RSRC2-depleted cells to confirm specificity of observed phenotypes

  • Overexpress C1QTNF1-AS1 in RSRC2-depleted cells to test RNA-mediated rescue

This approach has revealed that loss of RSRC2 leads to significant mitotic defects, including chromosome congression abnormalities and reduced centrin levels, indicating defects in centriole assembly during mitosis .

What methodology should be employed to investigate RSRC2's role in alternative splicing using RSRC2 antibodies?

To study RSRC2's function in splicing regulation:

• ChIP-seq analysis using RSRC2 antibodies to identify genomic binding sites

• RNA-seq comparison between control and RSRC2-depleted cells

• rMATS analysis to identify differentially spliced exons upon RSRC2 depletion

• Validation of splicing alterations:

  • RT-PCR with exon-specific primers

  • Capillary gel electrophoresis to quantify exon inclusion/exclusion rates

• Functional assessment of alternative splicing events:

  • Focus on mitotic regulators (e.g., PCNT, CDK5RAP2, CENPE)

  • Analyze the impact of splicing changes on protein function

This methodological approach has established that RSRC2 regulates alternative splicing of specific mitotic genes, with exon skipping in PCNT potentially inducing premature stop codons and contributing to mitotic defects .

How can RSRC2 antibodies be applied to investigate tumor suppressor functions in triple-negative breast cancer?

For investigating RSRC2's tumor suppressor role in TNBC:

• Tissue expression analysis:

  • Compare RSRC2 protein levels between TNBC tissues and other breast cancer subtypes

  • Correlate expression with patient prognosis using tissue microarrays

• Mechanistic studies:

  • Create stable RSRC2-overexpressing and RSRC2-knockout cell lines

  • Assess effects on proliferation, invasion, and drug resistance using functional assays

  • Investigate SCIN as a transcriptional target of RSRC2 using ChIP-qPCR and luciferase reporter assays

• Signaling pathway analysis:

  • Perform Western blot analysis to determine how RSRC2 expression affects downstream pathways

  • Identify potential therapeutic vulnerabilities in RSRC2-low tumors

These approaches have revealed that RSRC2 expression is significantly reduced in TNBC compared to other molecular subtypes, and low RSRC2 expression correlates with worse prognosis in breast cancer patients .

What are the appropriate experimental controls when studying RSRC2 expression patterns in cancer tissues?

When investigating RSRC2 expression in cancer tissues, implement these critical controls:

• For immunohistochemistry:

  • Positive control: Normal tissues known to express RSRC2

  • Negative control: RSRC2-knockout cell lines or tissues

  • Isotype control: Primary antibody replaced with matched IgG

  • Antibody validation: Western blot confirmation of specificity

• For expression analysis:

  • Include multiple cancer subtypes for comparison

  • Match cases and controls for age, sex, and other relevant clinical parameters

  • Use multiple reference genes for qPCR normalization

  • Validate findings with protein-level analysis (Western blot or IHC)

• For prognostic correlations:

  • Stratify patients based on RSRC2 expression levels

  • Control for confounding factors (tumor stage, grade, treatment history)

  • Perform multivariate analysis to determine independent prognostic value

These controls have helped establish that RSRC2 expression is significantly lower in multiple cancer types compared to normal tissues, including esophageal cancer, pancreatic ductal carcinoma, and triple-negative breast cancer .

How should I address inconsistent results when working with RSRC2 antibodies in different cell lines?

When facing inconsistent results across cell lines:

• Cell line-specific considerations:

  • Verify endogenous RSRC2 expression levels in each cell line by RT-qPCR and Western blot

  • Consider differences in RSRC2 isoform expression (short vs. long isoforms)

  • Account for potential splicing variations mediated by factors like TRA2A

• Methodological adjustments:

  • Optimize antibody concentration for each cell line

  • Adjust fixation and permeabilization conditions based on cell type

  • Consider cell cycle synchronization for mitosis-related experiments

• Validation approaches:

  • Use multiple antibodies targeting different RSRC2 epitopes

  • Create control cell lines with RSRC2 overexpression or knockout

  • Verify results with orthogonal techniques (e.g., fluorescent tagging of RSRC2)

Research has shown that RSRC2 expression and function can vary significantly between cancer cell lines, with varying effects on processes like drug sensitivity in different contexts .

What strategies can overcome challenges in detecting RNA-protein interactions involving RSRC2?

For investigating RSRC2-RNA interactions:

• Low-abundance RNA detection:

  • Use highly sensitive methods like incPRINT assay

  • Consider RNA amplification techniques for low-copy transcripts like C1QTNF1-AS1

  • Implement 3D super-resolution microscopy for visualizing RNA-protein interactions at centrosomes

• Interaction validation approaches:

  • Perform RNA immunoprecipitation followed by qPCR

  • Use orthogonal methods like CLIP-seq or RNA-protein pull-down assays

  • Include RNA specificity controls (e.g., GAPDH) and protein specificity controls

• Structural analysis:

  • Consider methods such as in vivo SHAPE-Map or COMRADES to identify structural elements in lncRNAs that mediate RSRC2 interaction

  • Investigate whether RNA structure or short elements within C1QTNF1-AS1 contribute to interactions with RSRC2

These approaches have been suggested for overcoming the challenges in studying RSRC2's interaction with the low-copy-number lncRNA C1QTNF1-AS1, which plays a role in facilitating error-free mitosis .